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Supplementary Figure 1.  Assessment of interference from common interference agents in the 
measurement of κ FLC (top) and λ FLC (bottom) by Seralite®. Change (mg/L) as a result of interference (x-
axes) was assessed by adding interference agents (y-axes) to serum containing normal κ (12.72 mg/L) and λ 
(10.88 mg/L) FLC levels. The concentration of interference agents is the final concentration in the sample.  
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Supplementary Figure 2.  Lot-to-lot variation from three independent lots of Seralite® for κ (left) and λ 
(right) when measuring 65 samples containing varying levels of free light chains.  
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Supplementary Table 1. Precision data using samples with varying concentrations of free light chains For 
intra- and inter-day precision samples with the following concentrations were used: normal (15.9 mg/L κ 
FLC, 13.4 mg/L λ FLC), elevated (51.8 mg/L κ FLC,  40.5 mg/L λ FLC) and highly-elevated (136.6 mg/L κ 
FLC,  136.7 mg/L λ FLC). For intra-reader precision samples with the following concentrations were used: 
normal (11.7 mg/L κ FLC, 8.8 mg/L λ FLC), elevated (42.1 mg/L κ FLC, 48.6 mg/L λ FLC) and highly-
elevated (156.7 mg/L κ FLC, 147.6 mg/L λ FL
CV %  Intra-day Inter-day Intra-reader 
Κ FLC      
Normal  8.1 5.7 5.5 
Elevated  8.1 3.6 3.1 
Highly-elevated   9.6 3.9 4.5 
λ FLC      
Normal   8.5 5.1 4.8 
Elevated  7.4 4.6 2.0 
Highly-elevated  9.0 7.1 2.6 
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Supplementary Table 2.  Stability of FLC concentrations measured using Seralite for samples with varying concentrations of FLCs: low, normal, elevated and high.  
Data shown is the median change in FLC concentration from baseline (mg/L) across three different testing conditions: ambient room temperature (21–24°C), 
refrigeration (3–5 °C) and freeze-thawing.  Samples stored at room temperature where tested at 0, 1, 8, 24, 48 and 72h. Samples stored in the fridge were tested at 0, 
1, 2, 3, 4 and 7 days. To test the effects of freeze thaw cycles, samples were tested on day 0 then frozen and re-tested daily over 6 consecutive days.  
 Low Normal  Elevated  High  
 Κ 
4.5 mg/L  
λ 
6.7 mg/L 
Κ 
13.5 mg/L 
λ 
10.9 mg/L 
Κ 
38.8 mg/L  
λ 
40.4 mg/L 
Κ 
124.8 mg/L 
λ 
122.0 mg/L  
Ambient room 
temperature  
21–24°C:  
0–72h  
0.7 1.4 -2.1  -0.4 -3.1 -0.2 -7.8 -7.8 
3–5°C:  
0–7 days  
0.7 1.3 -0.1 -0.3 0.4 1.3 2.3  1.6  
Freeze thaw 
6 cycles  
0.8 0.4 1.1 1.4 -0.5 2.9 3.3 4.7 
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Supplementary Table 3. Samples from multiple myeloma patients previously shown to give erroneously low results by Freelite® due to antigen excess were 
analysed using Seralite®.  Grey boxes highlight where antigen excess resulted in incorrect diagnosis using the standard dilution on Freelite®: patient 1 changes from a 
lambda to kappa diagnosis with re-dilution; patient 5 initially demonstrated a ratio within the normal diagnostic range (0.26–1.65) but then indicated a monoclonal 
lambda FLC with re-dilution. Seralite® was able to correctly identify all monoclonal FLCs in these patients using the ratio obtain from the standard dilution.  
 Freelite® 
(RocheHitachiCobas®C501)  
Standard dilution (κ 1 in 5, λ 1 in 8)  
Freelite® 
(RocheHitachiCobas®C501)  
Offline dilution  ( 1 in 100)  
Seralite® dual Κ and λ lateral 
flow device  
Standard dilution (1 in 3)  
Seralite® 
Offline dilution 
(1 in 20/1 in 400) 
Sample 
and 
involved 
FLC  
Κ λ Κ:λ Κ λ Κ:λ Κ λ Κ:λ Κ λ Κ:λ 
1 - κ 0.77 6.35 0.12 664  105 78.8 < 2.5  > 32    
2 - κ 37.64 8.66 4.3 31594  3648 > 200 3.4 >58 22320  6565 
3 - λ 5.63 39.86 0.14  695 0.01 < 2.5 184.2 < 0.013    
4 - κ 41.47 24.27 1.7 454  19 54.5 11.7 4.7    
5 - λ 6.51 15.63 0.42  1772 0.01 < 2.5  > 200 < 0.01  39480 >0.0006 
6 - κ 22.09 10.77 2.05 5435  505 > 200 6.7 > 30 4960  740 
7 - κ 51.05 8.58 5.95 562  66 > 200 < 2.5 > 80 530  >212 
8 - κ 31.31 5.00 6.26 3652  3652 135.5 < 2.5 > 54    
9 - κ 44.35 6.31 7.02 6640  1052 57.2 < 2.5 > 23    
10 - κ 46.85 9.48 4.94 1611  170 59 13.7 4.3    
 
